Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794, “Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (Mini-Hyper-CVD) as Front-Line Therapy for Older Patients (≥ 60 years) With Acute Lymphoblastic Leukemia,” presented by Elias Jabbour, MD.
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study.”
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Complications After Splenectomy in Adult Chronic Immune Thrombocytopenia With a Minimum Follow-up of 10 Years: First Results From a Single-Center Case-Control Study in 140 Patients With Primary ITP,” presented by Lan-huong Thai.
